Find information on thousands of medical conditions and prescription drugs.

Zafirlukast

Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma. Available as a tablet, it blocks the action of leukotriene C4 on its receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.

Zafirlukast is marketed by AstraZeneca with the brand names Accolate, Accoleit, and Vanticon. It was the first LTRA to be marketed in the USA and is now approved in over 60 countries, including the UK, Japan, Italy, Spain, Canada, Brazil and China.

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Zafirlukast
Zagam
Zalcitabine
Zaleplon
Zanaflex
Zanamivir
Zantac
Zarontin
Zelnorm
Zerit
Zestoretic
Zestril
Zetia
Zevalin
Ziagen
Zidovudine
Zileuton
Ziprasidone
Zithromax
Zocor
Zofran
Zoladex
Zoledronic acid
Zolmitriptan
Zoloft
Zolpidem
Zometa
Zomig
Zonegran
Zonisamide
Zopiclone
Zosyn
Zovia
Zovirax
Zyban
Zymar
Zyprexa
Zyrtec
Zyvox

Read more at Wikipedia.org


[List your site here Free!]


Effect Of Switching Patients With Asthma From Low-Dose Inhaled Corticosteroid Therapy To Low-Dose Fluticasone Or Zafirlukast - Abstract
From CHEST, 10/1/99 by Kathleen A Rickard

Purpose: To evaluate asthma control in patients switched from a fixed dose of beclomethasone (BDP) or triamcinolone (TAA) to low-dose fluticasone propionate (FP) or zafirlukast (ZAF).

Methods: Patients (males and females [is greater than or equal to] 12 years of age, [FEV.sub.1] = 60 to 85% of predicted normal) using a fixed dose of BDP (168 to 336 mcg/day) or TAA (400 to 800 mcg/day) for [is greater than or equal to] 4 weeks were randomized to FP aerosol (88mcg BID) or ZAF (20mg BID) for 6 weeks using a double-blind, double-dummy, parallel-group design. Clinic [FEV.sub.1] measurements and daily PEF, asthma symptoms, albuterol use, and adverse events were collected.

Results: Treatment with FP resulted in significantly greater improvements in measures of pulmonary function and symptom control as compared to ZAF. At endpoint, rescue albuterol use decreased with FP and increased with ZAF (P [is less than] 0.001). Significantly fewer (P=0.006) asthma exacerbations occurred with FP (n=2) as compared to ZAF (n= 12) and withdrawals due to lack of efficacy were reported for 5 (2%) FP patients and 29 (13%) ZAF patients. Adverse event profiles were similar.

(*) P<0.001 vs. ZAF

Conclusion: Switching patients from BDP or TAA to FP resulted in greater improvements in measures of pulmonary function and symptom control compared to ZAF.

Clinical Implications: For patients with stable, persistent asthma who are taking low doses of ICS, switching to a low-dose of FP may result in improved asthma control, while switching to ZAF monotherapy may result in reduced asthma control.

Grant Support by: Glaxo Wellcome Inc.

Kathleen A Rickard, MD(*); P Pepsin, RN; S Srebro, MD; L Edwards, PhD and FP Study Group. Medical Affairs, Glaxo Wellcome Inc, Research Triangle Park, NC.3

COPYRIGHT 1999 American College of Chest Physicians
COPYRIGHT 2000 Gale Group

Return to Zafirlukast
Home Contact Resources Exchange Links ebay